CYP3A4

Pharmacokinetics

Helicobacter pylori

Alfentanil

Dermatology

Midazolam

Anesthesia

Sedation

Clarithromycin

Itraconazole

Digoxin

Tuberculosis

Fentanyl

Cytochrome P450

Metabolism

Antifungal

Internal medicine

Pathology

Physiologically based pharmacokinetic modelling

Heart failure

Rifampicin

Pharmacology

Medicine

CPT Pharmacometrics & Systems Pharmacology

According to current US Food and Drug Administration ( FDA ) and European Medicines Agency ( EMA ) guidance documents, physiologically based pharmacokinetic ( PBPK ) modeling is a powerful tool to explore and quantitatively predict drug‐drug interactions ( DDI s) and may offer an alternative to dedicated clinical trials. This study provides whole‐body PBPK models of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin within the Open Systems Pharmacology ( OSP ) Suite. All models were built independently, coupled using reported interaction parameters, and mutually evaluated to verify their predictive performance by simulating published clinical DDI studies. In total, 112 studies were used for model development and 57 studies for DDI prediction. 93% of the predicted area under the plasma concentration‐time curve ( AUC ) ratios and 94% of the peak plasma concentration (C max ) ratios are within twofold of the observed values. This study lays a cornerstone for the qualification of the OSP platform with regard to reliable PBPK predictions of enzyme‐mediated and transporter‐mediated DDI s during model‐informed drug development. All presented models are provided open‐source and transparently documented.

PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin